JAMA: Longest OS Results for the Treatment of Extensive Small Cell Lung Cancer by Slulizumab (ASTRUM-005 Study)

Small cell lung cancer accounts for about 15% to 20% of bronchial lung cancer, and is the most aggressive subtype of lung cancer, divided into limited small cell lung cancer (LS-SCLC) and ES-SCLC
.

On September 27, 2022, the ASTRUM-005 study, an international multicenter Phase 3 clinical study led by Professor Cheng Ying, was just published in the Journal of the American Medical Association (JAMA), one of the world's top four medical journals, becoming the world's first clinical study
of small cell lung cancer immunotherapy to be published in the main journal of JAMA.

ASTRUM-005 research is a phase III clinical study of Henlius's self-developed anti-PD-1 monoclonal antibody H drug Hansi-like (sluliumab) combined with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC ®), and after Professor Cheng Ying first reported the results at the 2022 ASCO Annual Meeting, it has attracted widespread attention
from global peers.

It is expected to benefit the world and fill the clinical gap